Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL)

Trial Profile

Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2 (I-SPY 2 TRIAL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Ganetespib (Primary) ; Ganitumab (Primary) ; MK 2206 (Primary) ; Neratinib (Primary) ; Patritumab (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trebananib (Primary) ; Veliparib (Primary) ; Carboplatin; Conatumumab; Cyclophosphamide; Doxorubicin; Figitumumab; Metformin; Paclitaxel; Talazoparib; Trastuzumab emtansine
  • Indications Early breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms I-SPY-2
  • Most Recent Events

    • 13 Jun 2017 Results published in an Agendia media release.
    • 05 Jun 2017 Results from the parant study published in a Merck AG Media Release.
    • 05 Jun 2017 According to a Merck AG media release, data from the parant trial (NCT01042379) will be presented at at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and will also be presented in subsequent Best of ASCO events scheduled throughout the year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top